Conjugating PD-1 or CTLA-4 antibodies with ECM targeting agents, or fusing cytokines to ECM targeting agents for tumor localization have demonstrated positive pre-clinical results (135, 136). The gene discussed is CTLA4; the disease is neoplasm.